Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $73
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $48 to $73.
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $48 to $73.